Key result
Interferon alpha-2b induced an impressive and ongoing partial regression of the primary tumor and lung metastases in a patient with chemoresistant alveolar soft-part sarcoma.
Why the study?
Does interferon alpha-2b improve tumour response in a patient with alveolar soft-part sarcoma unresponsive to chemotherapy?
Case Report (n=1)
Does interferon alpha-2b improve tumour response in a patient with alveolar soft-part sarcoma unresponsive to chemotherapy?
Interferon alpha-2b may induce a tumour response in alveolar soft-part sarcoma, though treatment can be limited by severe psychiatric side effects like psychosis.
May warrant consideration in chemoresistant alveolar soft-part sarcoma; single-case report leaves open efficacy, durability, and psychiatric safety.
A 23-year-old woman with an alveolar soft-part sarcoma of her calf with pulmonary metastases unresponsive to chemotherapy is described. Interferon (IFN) alpha-2b induced an impressive tumour response still ongoing after IFN treatment had to be stopped because of a psychosis. An explanation of this effect is still speculative.
No takes yet. Share an insight, caveat, or question.
Roozendaal et al. (2003) conducted a case report in Alveolar soft-part sarcoma (n=1). Interferon alpha-2b was evaluated on Tumour response. Interferon alpha-2b induced an impressive and ongoing partial regression of the primary tumor and lung metastases in a patient with chemoresistant alveolar soft-part sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: